NCT06172894 - PBMC-based Leukocyte Immunotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 22, 2023

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2024

Conditions

Advanced Solid Tumor

Interventions

DRUG

APN401

APN401 is a suspension of viable peripheral blood mononuclear cells (PBMCs) from an individual patient that have been transfected with a small interfering ribonucleic acid (siRNA) to reduce Cbl-b expression. It is administered intravenously in 3-weekly intervals (i.e. every 21 days) for a maximum of 4 treatment cycles.

Trial Locations (4)

1090

Medizinische Universität Wien, Universitätsklinik für Transfusionsmedizin und Zelltherapie, Vienna

4010

Ordensklinikum Linz, Barmherzige Schwestern, Abteilung für Hals-, Nasen-, Ohrenheilkunde, Linz

5020

Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and Immunology Trials (CCCIT), Salzburg

6020

Medizinische Universität Innsbruck, Universitätsklinik für Innere Medizin V, Hämatologie und internistische Onkologie, Innsbruck

All Listed Sponsors

lead

invIOs GmbH

INDUSTRY